Exosomal biomarkers in Down syndrome and Alzheimer's disease
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify early signs of dementia in this population. The discovery of blood biomarkers predictive of dementia onset and/or progression in DS is critical for developing effective clinical diagnostics. Our recent studies show that neuron‐derived exosomes, which are small extracellular vesicles secreted by most cells in the body, contain elevated levels of amyloid‐beta peptides and phosphorylated‐Tau that could indicate a preclinical AD phase in people with DS starting in childhood. We also found that the relative levels of these biomarkers were altered following dementia onset. Exosome release and signaling are dependent on cellular redox homeostasis as well as on inflammatory processes, and exosomes may be involved in the immune response, suggesting a dual role as both triggers of inflammation in the brain and propagators of inflammatory signals between brain regions. Based on recently reported connections between inflammatory processes and exosome release, the elevated neuroinflammatory state observed in people with DS may affect exosomal AD biomarkers. Herein, we discuss findings from studies of people with DS, people with DS and AD (DS‐AD), and mouse models of DS showing new connections between neuroinflammatory pathways, oxidative stress, exosomes, and exosome‐mediated signaling, which may inform future AD diagnostics, preventions, and treatments in the DS population as well as in the general population. HIGHLIGHTSExosome technology can detect AD biomarkers decades prior to the onset of symptoms.Exosome signaling and release are affected by both oxidative homeostasis and inflammation.Exosomes may deliver therapies targeting oxidative stress, inflammation, and brain pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Since the 1980s, studies of post mortem brain specimens from AD patients have revealed significant elevations in neuroinflammatory markers [119,46,47,6,97].”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
DAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794
Regulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260 · cited 1×
“In support of this, a recent study demonstrated that IFN signaling resulted in viral RNA transmission to DCs by exosomes, which again induced the innate immune response in these cells [106].”
ResultOxidative stress and autophagy: The clash between damage and metabolic needs
Filomeni, G., De Zio, D., & Cecconi, F. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.150 · Cited by 2,195 · cited 1×
“Indeed, ROS may serve as one of the main intracellular signal transducers that sustains autophagy, but this important physiological process becomes inefficient during aging and in neurodegenerative diseases [31].”
BackgroundAlzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 2×
“cholinergic neurons (BFCNs), locus coeruleus (LC) noradrenergic (NE) neurons, certain hippocampal neuronal populations [112,74,79], and neurons in certain cortical areas [111,129], similar to the neurodegeneration observed in idiopathic AD [141].”
BackgroundAge-dependent dysregulation of innate immunity
Shaw, A. C., Goldstein, D. R., & Montgomery, R. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3547 · Cited by 1,061 · cited 1×
“Since the 1980s, studies of post mortem brain specimens from AD patients have revealed significant elevations in neuroinflammatory markers [119,46,47,6,97].”
BackgroundFiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
The S100B story: from biomarker to active factor in neural injury
Michetti, F., D'Ambrosi, N., Toesca, A., Puglisi, M. A., Serrano, A., Marchese, E., Corvino, V., & Geloso, M. C. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14574 · Cited by 410
The Origin and Functions of Exosomes in Cancer
Rajagopal, C., & Harikumar, K. B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00066 · Cited by 271
Suicide and Microglia: Recent Findings and Future Perspectives Based on Human Studies
Suzuki, H., Ohgidani, M., Kuwano, N., Chrétien, F., Lorin de la Grandmaison, G., Onaya, M., Tominaga, I., Setoyama, D., Kang, D., Mimura, M., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00031 · Cited by 198
“On the other hand, brain-derived exosomes have recently been a focus in understanding the pathophysiology of brain diseases without using brain biopsy (Yuyama et al., 2012; Goetzl et al., 2016; Hamlett et al., 2018).”
BackgroundPropagation of Tau via Extracellular Vesicles
Pérez, M., Avila, J., & Hernández, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00698 · Cited by 118
“Also, tau exosomes could be used as biomarkers not only for AD but also Down syndrome and Parkinson’s disease (Shi et al., 2016; Hamlett et al., 2018).”
Background
Metadata
- Authors
- Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A.-C.
- Venue
- Free Radical Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 114
- Pages
- 110-121
- ISSN
- 0891-5849 (ISSN-L)
- OpenAlex
- W2752766390
- Cited by
- 76
- References
- 38
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exosomal biomarkers in Down syndrome and Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.freeradbiomed.2017.08.028
- The paper
- Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A.-C. (2018). Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2017.08.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.